H. Lundbeck A/S
HLUN-A
Rang in Aktien
#2988
H. Lundbeck A/S engages in the research, development, manufacturing, and... H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson’s disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson’s disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark.
Aktienkurs
$7.41
Marktkapitalisierung
$6.17B
Veränderung (1 Tag)
3.44%
Veränderung (1 Jahr)
33.63%
Land
DK
Handel H. Lundbeck A/S (HLUN-A)
Kategorie
Healthcare
Dividendenrendite-Verlauf für H. Lundbeck A/S (HLUN-A)
Dividendenrendite (TTM) von H. Lundbeck A/S (Aktienkürzel: HLUN-A) zum 2024-12-31: 1.69%
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 1.82%
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 1.82%
Dividendenrendite-Verlauf für H. Lundbeck A/S (HLUN-A) von 2004 bis 2026
Dividendenrendite am Ende jedes Jahres (TTM)
| Jahr | Dividendenrendite | ändert |
|---|---|---|
| 2026 (TTM) | 2.42% | 10.00% |
| 2025 | 2.20% | 30.18% |
| 2024 | 1.69% | -4.52% |
| 2023 | 1.77% | 15.69% |
| 2022 | 1.53% | -20.31% |
| 2021 | 1.92% | -84.79% |
| 2020 | 12.62% | -65.82% |
| 2019 | 36.92% | 50.02% |
| 2018 | 24.61% | 227.26% |
| 2017 | 7.52% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | -100.00% |
| 2014 | 8.53% | 38.70% |
| 2013 | 6.15% | -42.79% |
| 2012 | 10.75% | -7.33% |
| 2011 | 11.60% | 22.88% |
| 2010 | 9.44% | 33.33% |
| 2009 | 7.08% | -10.15% |
| 2008 | 7.88% | 61.81% |
| 2007 | 4.87% | -24.85% |
| 2006 | 6.48% | -4.71% |
| 2005 | 6.80% | 24.09% |
| 2004 | 5.48% | 0.00% |
Dividendenrenditen (TTM) für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | Dividendenrendite | Land |
|---|---|---|
| 1.57% |
US
|
|
| 0.00% |
SE
|
|
| 0.00% |
FR
|
|
| 0.00% |
IT
|
|
| 0.00% |
US
|
